Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06606847 | A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) | PHASE2 | ACTIVE NOT_RECRUITING | 30 | — | — | Sep 24, 2024 | Mar 30, 2027 | May 15, 2026 | 11 | Russia |
PFS12 is defined as the Kaplan-Meier estimate of PFS at 12 months per RECIST 1.1 as assessed by the investigator.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | durvalumab plus oleclumab as an IV infusions |
| Name | Type | Description |
|---|---|---|
| Oleclumab | DRUG | Oleclumab IV (intravenous infusion) |
| Durvalumab | DRUG | Durvalumab IV (intravenous infusion) |
INCLUSION CRITERIA: * Participant must be ≥ 18 years at the time of screening. * Histologically-documented NSCLC and have been treated with concurrent or sequential CRT for locally advanced, unresectable (Stage III) disease. * Documented tumour PD-L1 status by qualified lab (local or central). * Do...